Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 80 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Pipeline Review, H1 2016', provides in depth analysis on Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) 
- The report reviews Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) Overview 8
Therapeutics Development 9
Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Products under Development by Stage of Development 9
Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Products under Development by Therapy Area 10
Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Products under Development by Indication 11
Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Products under Development by Companies 15
Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Products under Development by Universities/Institutes 19
Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Therapeutics Assessment 21
Assessment by Monotherapy/Combination Products 21
Assessment by Mechanism of Action 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Companies Involved in Therapeutics Development 26
AbbVie Inc. 26
Advenchen Laboratories, LLC 27
Aeterna Zentaris Inc. 28
Amgen Inc. 29
Astex Pharmaceuticals, Inc. 30
AstraZeneca Plc 31
Chipscreen Biosciences Ltd 32
Merck KGaA 33
Nemucore Medical Innovations, Inc. 34
Sanofi 35
Sareum Holdings Plc 36
Vertex Pharmaceuticals Incorporated 37
Vichem Chemie Research Ltd. 38
Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Drug Profiles 39
AL-8326 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
AMG-900 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
AT-9283 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
AZD-2811 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
CS-2164 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
danusertib - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
ilorasertib - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
NMI-900 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
SAR-156497 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
SAR-3 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
SAR-4 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecule to Inhibit Aurora B Kinase for Cancer - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecules to Inhibit Aurora A/B Kinase for Oncology - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecules to Inhibit Aurora B Kinase for Oncology - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecules to Inhibit ERK2 and Aurora B Kinase for Oncology - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
VE-465 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Dormant Projects 60
Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Discontinued Products 67
Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) - Featured News & Press Releases 69
May 10, 2016: Data Published in Journal of Controlled Release Demonstrate Flexibility of ACCURINS to Encapsulate a Broad Range of Physically and Chemically Diverse Payloads with High Encapsulation Efficiency and Tunable Release Kinetics 69
Feb 10, 2016: AZD2811 ACCURINS Data Published in Science Translational Medicine Highlight One of the First Applications of Nanomedicine to Molecularly Targeted Cancer Therapies 70
Nov 18, 2015: BIND Therapeutics Announces Initiation of Clinical Studies with Accurin AZD2811 in Solid Tumors 70
Sep 15, 2015: US and European Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors 72
Jun 23, 2015: BIND Therapeutics Announces FDA Authorization of First-in-Human Clinical Trial with AstraZeneca's Aurora B Kinase Inhibitor Accurin AZD2811 72
Apr 22, 2015: BIND Therapeutics Presents Data Highlighting Ability of Accurin drug candidate AZD2811 to Accumulate in Target Tissue at AACR Annual Meeting 2015 73
Mar 18, 2015: Data from Abstracts Validating Potential of BIND Therapeutics AZD2811 to be Presented at American Association for Cancer Research Annual Meeting 74
Mar 05, 2014: BIND Therapeutics to Present Data on Barasertib at the AACR 2014 Annual Meeting 75
Jul 15, 2013: Preclinical Development Candidate Selected for Aurora+FLT3 Inhibitor Programme 75
May 16, 2012: Astex Pharmaceuticals To Present Data On AT9283 At ASCO Annual Meeting 75
Jan 27, 2012: Cancer Research UK Launches Trial Of New Drug To Treat Acute Childhood Leukemia 76
Dec 01, 2010: Astex To Present Encouraging Data On AT9283 In Combination With Docetaxel For Treatment Of Non-Hodgkin's Lymphoma 76
Dec 01, 2010: Astex To Present Encouraging Data On AT9283 In Combination With Lenalidomide For Treatment Of Multiple Myeloma At ASH Annual Meeting 77
Nov 04, 2010: Astex And NCIC Clinical Trials Group Initiate Phase II Clinical Study Of AT9283 In Multiple Myeloma 77
Nov 23, 2009: Astex Granted Orphan Drug Status For AT9283 In AML In USA And Europe 78
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 79
Disclaimer 80

List of Tables

Number of Products under Development for, H1 2016 9
Number of Products under Development by Therapy Area, H1 2016 10
Number of Products under Development by Indication, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Early Stage Products, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Development by Companies, H1 2016 (Contd..1) 17
Products under Development by Companies, H1 2016 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2016 19
Products under Investigation by Universities/Institutes, H1 2016 20
Assessment by Monotherapy/Combination Products, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 22
Number of Products by Stage and Route of Administration, H1 2016 24
Number of Products by Stage and Molecule Type, H1 2016 25
Pipeline by AbbVie Inc., H1 2016 26
Pipeline by Advenchen Laboratories, LLC, H1 2016 27
Pipeline by Aeterna Zentaris Inc., H1 2016 28
Pipeline by Amgen Inc., H1 2016 29
Pipeline by Astex Pharmaceuticals, Inc., H1 2016 30
Pipeline by AstraZeneca Plc, H1 2016 31
Pipeline by Chipscreen Biosciences Ltd, H1 2016 32
Pipeline by Merck KGaA, H1 2016 33
Pipeline by Nemucore Medical Innovations, Inc., H1 2016 34
Pipeline by Sanofi, H1 2016 35
Pipeline by Sareum Holdings Plc, H1 2016 36
Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 37
Pipeline by Vichem Chemie Research Ltd., H1 2016 38
Dormant Projects, H1 2016 60
Dormant Projects (Contd..1), H1 2016 61
Dormant Projects (Contd..2), H1 2016 62
Dormant Projects (Contd..3), H1 2016 63
Dormant Projects (Contd..4), H1 2016 64
Dormant Projects (Contd..5), H1 2016 65
Dormant Projects (Contd..6), H1 2016 66
Discontinued Products, H1 2016 67
Discontinued Products (Contd..1), H1 2016 68